Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peanut Hypersensitivity Clear all
Completed Phase 1 Interventional Results available

Boiled Peanut Oral Immunotherapy

NCT04090203
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Boiled Peanut Powder
Drug
Lead sponsor
Alton Melton
Other
Eligibility
1 Year to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated No phase listed Observational

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

NCT00557895
View directory record Official record
Conditions
Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional

Immunotherapy for Peanut Allergy

NCT00429429
View directory record Official record
Conditions
Allergy
Interventions
Sublingual immunotherapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 35 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 55 Years
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

NCT01955109
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
7 Years to 56 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy, Omalizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

AR101 Real-World Open-Label Extension Study

NCT03337542
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

NCT07220811
View directory record Official record
Conditions
Ig-E Mediated Food Allergy
Interventions
RPT904, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
12 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

NCT04984876
View directory record Official record
Conditions
Allergy, Peanut
Interventions
ligelizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 55 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Completed No phase listed Observational

An Observational Study of Childhood Food Allergy

NCT00356174
View directory record Official record
Conditions
Food Hypersensitivity, Peanut Hypersensitivity, Egg Hypersensitivity, Milk Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Months
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Predicting Peanut Anaphylaxis and Reducing Epinephrine

NCT05696236
View directory record Official record
Conditions
Anaphylaxis Food
Interventions
Transepidermal water loss (TEWL) monitor and stopping rules, Monitor (TEWL) without stopping rules
Device
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 5 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

NCT02920021
View directory record Official record
Conditions
Peanut Allergy
Interventions
Etokimab, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

NCT05440643
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

NCT05741476
View directory record Official record
Conditions
Allergy, Peanut
Interventions
DBV712, Placebo
Drug · Other
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 7 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

NCT02192866
View directory record Official record
Conditions
Peanut Allergies, Tree Nut Allergies, Other Food Allergies
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

NCT07210320
View directory record Official record
Conditions
Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions
Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray
Drug
Lead sponsor
Insignis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Salvage Peanut Oral Immunotherapy Study

NCT03251508
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Trichuris Suis Ova in Peanut and Tree Nut Allergy

NCT01070498
View directory record Official record
Conditions
Food Allergy
Interventions
Trichuris suis ova (TSO)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

NCT01274429
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jul 23, 2026, 2:10 PM EDT